A new CAR T-cell therapy for B-cell cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new type of CAR T-cell treatment called SHB-02-CD19 for people with B-cell cancers that have come back or not responded to at least two prior treatments. It may be an option if you cannot receive current commercial CAR T-cell therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a B-cell cancer (like lymphoma or leukemia) that expresses the CD19 protein.
- Your cancer has relapsed or not responded after at least 2 prior treatments, and you cannot get the current approved CAR T-cell therapy.
- You are between 1 and 80 years old.
- You have enough immune T-cells (CD3 count above 120 per microliter of blood) and good heart function (ejection fraction >45%).
- You have not received a prior CD19 CAR T-cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
This trial tests a new type of immunotherapy where your own immune cells are collected, modified to recognize and attack cancer cells, and then returned to your body. It may be an option for people with B-cell cancers that have not responded to other treatments.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has come back or did not respond to previous treatments.
This early-phase study tests “humanized” CD19 CAR-T therapy for people whose B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma (NHL) has come back or didn’t respond. It’s designed to help the immune system recognize and attack cancer cells carrying the CD19 marker.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.